Related Experiment Videos
Pulmonary metastases in pseudomyxoma peritonei syndrome
K D Mortman1, P A Sugarbaker, B M Shmookler
1Department of Surgery, Washington Cancer Institute, Washington Hospital Center, Washington, DC 20010, USA.
Background:
Pseudomyxoma peritonei (PMP) is a rare disease arising from a mucinous cystadenoma of appendiceal origin. The syndrome has been characterized by progressive growth of mucinous tumors, tense mucinous ascites, and ultimately death. Abdominal and pelvic recurrence after resection of intraperitoneal disease occurs in all patients unless adjunctive measures are taken. Local spread of PMP by direct extension to the pleural or pericardial space is uncommon but has been reported in the literature. Here we report development of pulmonary parenchymal metastases after treatment for PMP.
Methods:
The charts of 3 patients were retrospectively reviewed for the presentation and management of metastatic PMP.
Results:
Three patients underwent resection for pulmonary parenchymal metastases of PMP. All patients recovered uneventfully. The continue to do well after 2 to 8 years of follow-up.
Conclusions:
Pulmonary metastasectomy for PMP is safe and effective after treatment of intraperitoneal disease.
Insights
Pseudomyxoma peritonei (PMP) can spread to the lungs. Surgical removal of these pulmonary metastases (PMP lung spread) is safe and effective, offering good long-term outcomes for patients.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Pseudomyxoma peritonei (PMP) is a rare appendiceal neoplasm.
- Characterized by mucinous ascites and tumor progression.
- Intraperitoneal recurrence is common; pleural/pericardial spread is rare.